Safety of Medical Transition

“Is medical transition safe?” is one of the most frequently asked — and most exploited — questions in the debate about transgender people. It is posed by concerned parents, by patients considering the process, but also by those seeking arguments to restrict access to care. The answer, as with any medical treatment, is not a simple “yes” or “no”: it is a balance between risks and benefits, supported by decades of scientific evidence.

This article examines what meta-analyses, cohort studies, and international guidelines say about the safety of medical transition, without hiding real risks but contextualizing them honestly.

What “Safe” Means in Medicine

In medicine, no treatment is risk-free. Aspirin can cause gastrointestinal hemorrhages. Oral contraceptives increase thromboembolic risk. Knee replacements have a dissatisfaction rate approaching 20%. None of these treatments is called “dangerous” or “experimental”: they are evaluated based on their risk-benefit ratio.

The same principle applies to medical transition. The question is not “are there risks?” — there are, as with any medical intervention. The question is: do the benefits outweigh the risks? And the answer, according to peer-reviewed literature, is unequivocally yes for the vast majority of people who undertake this process.

What Meta-Analyses Say About the Benefits

The Cornell University Review

The What We Know project at Cornell University conducted one of the most comprehensive reviews available, analyzing over 4,000 studies and identifying 56 that directly assessed the impact of gender transition on transgender well-being [1]. The result: 93% of studies (52 out of 56) found positive effects from transition. Only 4 studies reported mixed or null results. None found that transition worsened overall well-being [1].

Documented benefits include improved quality of life, greater relationship satisfaction, increased self-esteem, and reduction in anxiety, depression, suicidal tendencies, and substance abuse [1]. The review also noted that positive outcomes have improved over time as surgical techniques and social support have progressed.

The Murad et al. Meta-Analysis

The meta-analysis by Murad et al. (2010), conducted at the Mayo Clinic and published in Clinical Endocrinology, analyzed 28 studies with 1,833 participants (1,093 trans women and 801 trans men). The results [2]:

• 80% reported significant improvement in gender dysphoria
• 78% reported improvement in psychological symptoms
• 80% reported improvement in quality of life
• 72% reported improvement in sexual function

These numbers do not describe an “experimental” treatment. They describe a treatment with efficacy rates comparable to or exceeding many established therapies in medicine.

The de Vries et al. Study on Young Adults

The longitudinal study by de Vries et al. (2014), published in Pediatrics, followed 55 young transgender adults who had received puberty suppression during adolescence, assessing them at three time points: before treatment began (mean age 13.6 years), at introduction of cross-sex hormones (mean age 16.7 years), and at least one year after reassignment surgery (mean age 20.7 years) [3].

Results showed consistent improvement in gender dysphoria, body image, global functioning, and life satisfaction. Depression, anxiety, and emotional and behavioral problems were significantly reduced. No participant expressed regret [3]. This study remains one of the primary references for the effectiveness of the Dutch protocol of puberty suppression followed by hormones and surgery.

Mental Health: The Impact Data

Medical transition is not just a matter of physical changes. Its impact on mental health is extensively and consistently documented.

Reduction of Depression and Suicidality

The study by Tordoff et al. (2022), published in JAMA Network Open, followed a cohort of 104 transgender and non-binary youth (ages 13-20) who had begun gender-affirming care. After 12 months, those who had received puberty blockers or hormones were 60% less likely to suffer from moderate or severe depression and 73% less likely to experience suicidal ideation compared to those who had not started treatment [9].

The most significant finding: those who had not started hormones within the first 3-6 months of clinic access showed a 2-3 fold increase in depressive symptoms and suicidal ideation [9]. This suggests that waiting lists and delays in access are not just a bureaucratic inconvenience but a clinical risk factor.

Surgery and Psychological Well-Being

The study by Almazan and Keuroghlian (2021), published in JAMA Surgery, analyzed data from 27,715 transgender adults from the US Transgender Survey. Individuals who had received at least one gender-affirming surgery showed [10]:

• 42% less psychological distress in the prior month
• 35% less likelihood of smoking in the prior year
• 44% less suicidal ideation in the prior year

These are not marginal numbers. They are clinically significant differences confirming that gender-affirming surgery, for those who desire it, has a measurable positive impact on mental health.

Satisfaction and Regret Rates

One of the most direct ways to assess the safety of a treatment is to ask patients whether they would do it again. In the case of medical transition, the data are clear.

Surgical Regret: Less Than 2%

The meta-analysis by Bustos et al. (2021), published in Plastic and Reconstructive Surgery — Global Open, analyzed 27 studies involving 7,928 transgender patients. The overall regret rate after gender-affirming surgery was 1% (95% confidence interval: less than 1% — 2%) [5].

The Amsterdam cohort study (Wiepjes et al., 2018), which followed 6,793 people between 1972 and 2015, reported regret rates after gonadectomy of 0.6% for trans women and 0.3% for trans men [4]. These numbers did not increase over time, despite the number of people in treatment growing 20-fold over the study period [4].

Comparison with Other Surgeries

To contextualize these numbers, the systematic review by Boyd et al. (2024), published in The American Journal of Surgery, compared surgical regret rates across different specialties [11]:

Surgery	Regret Rate
Gender-affirming surgery	~1%
Breast augmentation	5.1—9.1%
Bariatric surgery	2—14%
Knee replacement	~17%
Back surgery	up to 21%
Breast reconstruction	0—47.1%

Regret after gender-affirming surgery is among the lowest in all of medicine [11]. None of the other listed procedures is the subject of legislative campaigns to restrict access. This double standard is not justifiable on scientific grounds.

The Real Risks: An Honest Overview

Stating that medical transition is safe does not mean denying the existence of risks. It means these risks are known, manageable, and overall contained relative to the benefits. Let us examine them in detail.

Venous Thromboembolism (VTE)

The risk of deep vein thrombosis and pulmonary embolism is the most studied risk of estrogen therapy in trans women. A meta-analysis published in Frontiers in Endocrinology (2021) confirmed an increased VTE risk in trans women on estrogen therapy compared to the general population [12].

However, context matters. Risk is strongly influenced by the route of administration: oral estrogens carry significantly higher risk than transdermal formulations (patches or gel). Transdermal formulations show VTE risk comparable to the general population [12]. This is consistent with what is observed in cisgender women: oral contraceptives increase VTE risk to 3-9 cases per 10,000 women per year, compared to 1-5 in the general population. Transdermal estrogen therapy for trans women does not substantially exceed these values.

The Endocrine Society guidelines (2017) recommend preferring the transdermal route, especially in patients with additional risk factors (smoking, obesity, advanced age, family history of thrombosis) [7].

Cardiovascular Risk

The cohort study by Getahun et al. (2018), published in Annals of Internal Medicine, analyzed data from 2,842 trans women and 2,118 trans men in Kaiser Permanente health systems, comparing them with nearly 100,000 cisgender controls [6].

Results showed a moderate increase in cardiovascular events in trans women compared to cisgender women, but not compared to cisgender men [6]. In trans men, the risk profile shifted toward that typical of cisgender men. In both cases, absolute event rates remain low: approximately 3 VTE cases per 1,000 person-years in trans women, with lower rates of stroke and myocardial infarction [6].

This is not a “hidden danger”: it is a known risk profile, monitorable and manageable with regular checks of lipid profile, blood pressure, and blood parameters.

Bone Density

The systematic review and meta-analysis by Singh-Ospina et al. (2019), published in the Journal of the Endocrine Society, analyzed 19 studies involving 487 trans men and 812 trans women [13]. The results:

• In trans men: no significant difference in bone mineral density compared to cisgender women, in both cross-sectional and longitudinal studies. Testosterone maintains bone health [13].
• In trans women: no significant difference compared to cisgender men at the femoral neck, total femur, and lumbar spine. Longitudinal studies showed a slight but significant increase in lumbar bone density after 12 and 24 months of therapy [13].

In summary: hormone therapy does not compromise bone health. In some cases, it improves it. Monitoring via bone densitometry remains recommended, especially for trans women after possible gonadectomy [7].

Liver Effects

Effects on liver function are rare and generally mild. Guidelines recommend monitoring liver enzymes, especially in the first months of therapy and with oral administration [7]. Hormone therapy for trans people is not associated with a significant increase in the risk of serious liver disease in the monitored population.

Fertility

Hormone therapy affects fertility. Estrogens reduce spermatogenesis in trans women; testosterone can interrupt ovulation in trans men. These effects are generally reversible after therapy discontinuation, although complete recovery is not guaranteed, especially after prolonged treatment. The WPATH SOC-8 and Endocrine Society guidelines recommend discussing fertility preservation options (cryopreservation of sperm or oocytes) before starting treatment [7][8].

What International Medical Organizations Say

A powerful indicator of a treatment’s safety is the consensus of medical organizations that evaluate it. In the case of medical transition, the consensus is broad and unequivocal.

The World Professional Association for Transgender Health (WPATH) published in 2022 version 8 of the Standards of Care, the global reference document for transgender health [8]. The SOC-8, based on a systematic literature review, recommends hormone therapy and surgery as effective and appropriate treatments for people with gender incongruence, with detailed protocols for assessment, treatment, and monitoring.

The Endocrine Society published in 2017 its own clinical guidelines, recommending hormone therapy for people with gender dysphoria or gender incongruence, specifying protocols for dosing, monitoring, and side effect management [7].

The American Psychological Association (APA) adopted in 2021 a resolution opposing attempts to change people’s gender identity and supporting barrier-free access to evidence-based care for transgender people [14].

In addition, the World Health Organization (which in 2019 removed gender incongruence from the chapter on mental disorders in ICD-11), the American Medical Association, the American Academy of Pediatrics, the Royal College of Physicians, and dozens of other national and international medical organizations have taken similar positions.

There is not a single major medical organization in the world that classifies medical transition as “experimental” or “dangerous.” Scientific consensus is not an opinion: it is the result of decades of accumulated research.

Medical Transition Is Not Experimental

One of the most common narratives in media and political discourse is that medical transition is an “experiment” conducted on vulnerable people. This claim is false.

Cross-sex hormone therapy was first documented in the 1960s and 1970s. The first WPATH guidelines date to 1979. The Endocrine Society published its own recommendations in 2009, updating them in 2017 [7]. The Amsterdam cohort has been following patients since 1972 [4].

We are talking about over 50 years of clinical data, hundreds of peer-reviewed studies, thousands of patients followed longitudinally. For comparison, many commonly used medications have less extensive evidence bases.

The definition of “experimental” has a precise meaning in medicine: it refers to treatments in clinical study phases, not yet approved for current practice. Hormone therapy for trans people does not meet this definition. It is included in clinical guidelines, recommended by scientific societies, and covered by healthcare systems in dozens of countries.

The Importance of Monitoring

The safety of medical transition is not automatic: it depends on the quality of monitoring. The Endocrine Society guidelines (2017) recommend [7]:

• Hormone level checks every 3 months in the first year, then 1-2 times per year
• Complete blood count to monitor hemoglobin and polycythemia (especially in trans men)
• Lipid profile and blood glucose for cardiovascular risk
• Liver function in the first months and periodically
• Bone densitometry periodically, especially after gonadectomy
• Cancer screenings appropriate to individual clinical history (mammography, prostate screening)

This monitoring is not fundamentally different from what is required for any long-term hormone therapy: oral contraceptives, menopausal hormone replacement therapy, testosterone therapy for male hypogonadism. The difference is that for medical transition, monitoring is presented as proof of “dangerousness,” while for other treatments it is considered normal clinical practice.

Why Some Narratives Exaggerate the Risks

Public perception of medical transition safety is distorted by several factors.

Selective amplification of negative stories. Media tend to give space to stories of regret and complications, while the millions of positive outcomes do not make the news. This creates a distorted perception of the frequency of negative outcomes.

Confusion between absolute and relative risk. A “200% increase in risk” of thrombosis sounds alarming. But if the baseline risk is 1 in 10,000 per year, a 200% increase means 3 in 10,000 per year: a risk that remains very low in absolute terms. This distinction is rarely explained in public discourse.

Double standard in evaluation. The risks of medical transition are evaluated by a different standard than comparable treatments. Oral contraceptives have a similar thromboembolic risk profile, but no one proposes banning them. Knee replacements have a regret rate 17 times higher, but no one suggests restricting access [11]. The double standard suggests that the real concern is not patient safety.

Political exploitation. The real risks of medical transition — which exist, are documented, and are manageable — are used as arguments to deny access to care for all trans people, regardless of the individual risk-benefit balance. This is equivalent to proposing a ban on statins because they can cause myopathy: technically true, but profoundly misleading.

Omission of the risks of non-transition. The debate focuses almost exclusively on treatment risks, systematically ignoring the documented risks of withheld transition: depression, anxiety, self-harm, substance abuse, suicidal ideation [9][10]. The literature consistently shows that denying access to care is not a “cautious” choice — it is a choice with measurable clinical consequences.

The Risk-Benefit Balance

Summarizing the available evidence:

Documented benefits:

• Significant reduction in gender dysphoria (80% of patients) [2]
• Improved quality of life (80%) [2]
• Reduction in depression and anxiety (60-78%) [2][9]
• Reduction in suicidal ideation (44-73%) [9][10]
• Satisfaction rates exceeding 94% [1]
• Regret rates below 2% [5]

Documented risks:

• Moderate increase in thromboembolic risk (especially with oral estrogen, minimizable with transdermal route) [12]
• Lipid profile changes (monitorable) [7]
• Effects on fertility (partially reversible, manageable with preventive cryopreservation) [7][8]
• Rare liver effects (monitorable) [7]
• Moderately increased cardiovascular risk in trans women (monitorable) [6]

There is no medical treatment with this ratio of benefits to risks that is considered “unsafe.” Medical transition, when performed under medical supervision with adequate monitoring, is a safe, effective treatment with solid scientific evidence support.

A Note on Evidence Quality

It is important to be honest about research limitations. Many available studies are observational, not randomized controlled trials. Follow-up periods are sometimes short. Some studies have moderate sample sizes.

This does not mean the conclusions are unreliable. It means that, as in many areas of medicine, the evidence is imperfect but consistent. The direction of results is constant: medical transition improves the lives of trans people [1][2]. The consistency of this result across decades, countries, methodologies, and diverse populations is the strongest signal research can offer.

The answer to the question “is medical transition safe?” is not an act of faith: it is a reading of the data. And the data, with all their limitations, are clear.